Cantor


Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …

Why Galmed Pharmaceuticals (GLMD) Is a $59 Stock

Galmed Pharmaceuticals (NASDAQ:GLMD) shares are soaring nearly 20% in after-hours trading Wednesday, as the drug maker gets a vote of confidence from Cantor …

Dynavax Technologies Corporation (DVAX) Gains a Cantor Bull on Back of Compelling HBV Opportunity

Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.

Snap Inc (SNAP) Gets a Price Target Boost on Meaningful Upside Potential for Monetization Per Minute

Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.

Cantor Asserts That Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Loan Amendments Get Rid of Meaningful Overhang on Stock

Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.

Array Biopharma Inc’s (ARRY) BRAF-Mutant Melanoma Combo Treatment Gets a PDUFA Date; Cantor Chimes In

Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.

Health Insurance Innovations Inc Shares Face the Heat; Cantor Finds Weakness Unfounded

Analyst dismisses negative publicity haunting HIIQ as unjustified extrapolation from past settlements.